Study on ITS1 Gene of Iranian Trichomonas vaginalis by Molecular Methods
-
F Kazemi
,
H Hooshyar
,
B Zareikar
,
M Bandehpour
,
M Arbabi
,
S Talari
,
R Alizadeh
,
B Kazemi
Abstract
Background: Trichomoniasis is a worldwide protozoan parasitic disease and metronidazole is a choice drug for its treatment. Because of disease importance in public health and its controversial ideas about the prevalence of drug resistance, this study was carried out.
Methods: Fifty-two suspected vaginal samples were collected from 2006 to 2007 in Gynecology Maryam Hospital, Tehran, Iran. All isolates were examined by microscopic, culture and PCR techniques. The PCR products were analyzed by RFLP and CSGE methods and two suspected samples were sequenced.
Results: Trichomonas vaginalis was identified from all 52 samples. Of 52 isolates, 45 samples were successfully cultured and amplified by PCR except one. Seven were positive only by PCR. Finally, ITS1 fragment was successfully amplified in 51 of 52. CSGE analysis and PCR products digestion by MspI followed by sequencing showed nucleotide mutation at position 209 (C209T) of the ITS1 fragment in two (3.9%) of them.
Conclusion: The results showed mutation in ITS1 fragment of T. vaginalis in two (3.9%) of Iranian isolates which may be related to metronidazole resistance.
Petrin D, Delgaty K, Bhatt R, Garber G. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev. 1998; 11(2): 300-317.
Kiviat NB, Paavonen JA, Brockway J, Critchlow CW, Brunham RC, Stevens CE et al. Cytologic manifestations of cervical and vaginal infections. I. Epithelial and inflammatory cellular changes. JAMA. 1985; 253(7): 989-996.
Cotch MF, Pastorek JG, Nugent RP, Hillier SL, Gibbs RS, Martin DH- et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. Sex Transm Dis. 1997; 24(6): 353-360.
Zhang ZF, Begg CB. Is Trichomonas vaginalis a cause of cervical neoplasia? Results from a combined analysis of 24 studies. Int J Epidemiol. 1994; 23(4): 682-690.
Laga M, Manoka A, Kivuvu M, Malele B, Tuliza M, Nzila N, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS. 1993; 7(1): 95-102.
Cudmore SL, Delgaty KL, Hayward- McClelland SF, Petrin DP, Garber GE.- Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis. Clin Microbiol Rev.2004; 17(4): 783-793.
Durel P, Roiron V, Siboulet A, Borel LJ. Systemic treatment of Trichomoniasis with a derivative of nitroimidazole, 8823 RP. Br J Vener Dis. 1960; 36: 21-26.
Snipes LJ, Gamard PM, Narcisi EM, Beard CB, Lehmann T, Secor WE. Molecular epidemiology of metronidazole resistance in a population of Trichomonas vaginalis clinical isolates. J Clin Microbiol. 2000; 38(8): 3004-3009.
Centers for disease control and prevention. Sexually transmitted diseases treatment guidelines. Morb Mortal Wkly Rep.1993; 42(RR-14): 70-72.
Robinson SC. Trichomonal vaginitis resistantto metronidazole. Can Med Assoc J. 1962; 86(14): 665.
Perez S, Fernandez-Verdugo A, Perez F, Vazquez F. Prevalence of 5- nitroimidazole resistant Trichomonas vaginalis in Oviedo, Spain. Sex Transm Dis. 2001; 28(2): 115-116.
Schimd G,¼Narcisi¼E, Mosure D, Secor WE, Higgins J, Moreno H. Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med. 2001; 46 (6): 545-549.
Upcroft P, Upcroft JA. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin Microbiol Rev. 2001; 14(1): 150-164.
Land KM, Clemens DL, Johnson PJ. Loss of multiple hydrogenosomal proteins associated with organelle metabolism and high-level drug resistance in Trichomonads. Exp Parasitol. 2001; 97(2): 102-110.
Rasoloson D, Vanacova S, Tomkova E, Razga J, Hrdy I, Tachezy J, et al. Mechanism of in vitro development of resistance to metronidazole in Trichomonas vaginalis. Microbiology. 2002; 148(pt8): 2467-2477.
Meri T, Jokiranta TS, Suhonen L, Meri S. Resistance of Trichomonas vaginalis to metronidazole: Report of the first three cases from Finland and optimization of in vitro susceptibility testing under various oxygen concentrations. J Clin Microbiol. 2000; 38(2):763-7.
Krashin JW, Koumans EH, Bradshaw- Sydnor AC, Braxton JR, Evan Secor W, Sawyer MK, et al. Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population. Sex Transm Dis. 2010; 37(7): 440-444.
Butler SE, Augostini P, Secor WE. Mycoplasma homonis infection of Trichomonas vaginalis is not associated with metronidazole-resistant trichomoniasis in clinical isolates from the United States. Parasitol Res. 2010; 107(4): 1023-1027.
Limoncu ME, Kilimcioglu AA, Kurt O, Ostan I, Ozkutuk N and Ozbilgin A. Two novel serum-free media for the culture of Trichomonas vaginalis. Parasitol Res. 2007; 100(3): 599-602.
Ganguly A. An update on conformation sensitive gel electrophoresis. Hum Mutat. 2002; 19(4): 334-342.
Xiao JC, Xie LF, Fang SL, Gao MY, Zhu Y, Song LY, et al. Symbiosis of Mycoplasma hominis in Trichomonas vaginalis may link metronidazole resistance in vitro. Parasitol Res. 2006; 100(1):123-130.
Dunne RL, Dunn LA, Upcroft P, O’Donoghue PJ, Upcroft JA. Drug resistance in sexually transmitted protozoan Trichomonas vaginalis. Cell Res. 2003; 13(4): 239-249.
Wiwanitkit V. Identification of weak points prone for mutation in ferredoxin of Trichomonas vaginalis. Indian J Med Microbiol. 2008; 26(2): 158-159.
Upcroft JA, Dunn LA, Wal T, Tabrizi S, Delgadillo-Correa MG, Johnson PJ et al. Metronidazole resistance in Trichomonas vaginalis from highland women in Papua New Guinea. Sexual Health. 2009; 6(4): 334-338.
| Files | ||
| Issue | Vol 5 No 4 (2010) | |
| Section | Articles | |
| Keywords | ||
| Trichomonas vaginalis Mutation ITS1 fragment | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
